Chimeric antigen receptor (CAR) T cells targeting CD19 have changed the treatment landscape of patients with relapsed/refractory diffuse large B-cell lymphoma. Infections are one of the most frequent complications after CAR T-cell therapy. Most of these infections are bacterial, although viral infections can also occur in this setting. Adenovirus-induced hemorrhagic cystitis is a rare infectious complication and is usually observed after bone marrow or solid organ transplantation. Herein we report a case of adenovirus-induced hemorrhagic cystitis in a patient experiencing urinary symptoms within the first month after CAR T-cell infusion. Based on our experience and a literature review, we discuss the diagnostic approach and potential treatment options for this infrequent infection after CAR T-cell therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/imt-2023-0111 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[An adult case of adenovirus type 3 infection presenting as clinically mild encephalitis/encephalopathy with a reversible splenial lesion and increased IL-6 levels in the cerebrospinal fluid].
Rinsho Shinkeigaku
November 2024
Department of Neurology, Toyama Prefectural Central Hospital.
A 42-year-old Japanese man with a history hepatitis C who had undergone bone marrow transplantation for Burkitt lymphoma. He visited our hospital after developing a fever and sore throat. A computed tomography scan of the chest revealed pneumonia, and the patient was admitted to our hospital.
View Article and Find Full Text PDFThymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy.
Cell Rep Med
October 2024
State Key Laboratory of Pharmaceutical Biotechnology, National Institute of Healthcare Data Science at Nanjing University, Jiangsu Key Laboratory of Molecular Medicine, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Medical School & School of Life Sciences, Nanjing University, 22 Hankou Road, Nanjing 210093, China; Jinan Microecological Biomedicine Shandong Laboratory, Shounuo City Light West Block, Jinan, China. Electronic address:
Article Synopsis
- Oncolytic adenoviruses are being studied for their ability to kill cancer cells and modulate the immune response, but their potential immunosuppressive effects need further investigation.
- This study shows that type V adenoviruses can change the behavior of tumor-associated macrophages (TAMs) and increase regulatory T cells (Tregs) in the tumor microenvironment, which can hinder immune responses against tumors.
- Thymosin alpha 1 (Tα1) can reprogram these macrophages to support anti-tumor activity and enhance the effectiveness of the adenovirus in fighting cancer, indicating a promising direction for future cancer therapies.
Deletion of the RGD motif from the penton base in oncolytic adenoviruses enhances antitumor efficacy of combined CAR T cell therapy.
Mol Ther Oncol
September 2024
Cellular Biotechnology Unit, Instituto de Salud Carlos III, 28220 Madrid, Spain.
Oncolytic viruses often face challenges in achieving optimal antitumor immunity as standalone therapies. The penton base RGD-integrin interactions play a significant role in wild-type adenovirus-induced innate immune responses. To modify these responses, we present ISC301, a novel oncolytic adenovirus engineered by deleting the natural RGD motifs in the penton base while incorporating artificial RGD motifs in the fiber knobs.
View Article and Find Full Text PDFMixed-phenotype acute leukemia (MPAL) with -TKD mutations is a rare and challenging subtype of leukemia. Effective management strategies are crucial for improving patient outcomes. A 31-year-old man with -TKD-mutated MPAL achieved hematological remission through the JALSG ALL202-O protocol and gilteritinib, followed by cord blood transplantation (CBT).
View Article and Find Full Text PDFAdenovirus-induced hemorrhagic cystitis after CD19-targeted chimeric antigen receptor T-cell therapy in a patient with large B-cell lymphoma.
Immunotherapy
November 2023
Department of Hematology, Experimental Hematology, Vall d'Hebron Institute of Oncology, University Hospital Vall d'Hebron, 08035, Barcelona, Spain.
Chimeric antigen receptor (CAR) T cells targeting CD19 have changed the treatment landscape of patients with relapsed/refractory diffuse large B-cell lymphoma. Infections are one of the most frequent complications after CAR T-cell therapy. Most of these infections are bacterial, although viral infections can also occur in this setting.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!